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ABSTRACT 
The purpose of this thesis was to develop and/or evaluate assays for HIV viral load 
(VL) monitoring and HIV drug resistance testing of potential importance for research 
studies and clinical care in low- and middle income countries (LMICs). This was 
achieved using reverse transcriptase based (RT) assays and blood samples from 
Vietnamese and Swedish HIV-1 infected patients.  
In Paper I, HIV-1 obtained from 63 treatment-naïve Vietnamese patients was analysed 
by population sequencing and phylogenetic analysis with regard to transmitted drug 
resistance (TDR), subtype and the time of the most recent common ancestor (tMRCA). 
All strains belonged to HIV-1 CRF01_AE and TDR was found in 6.3% of the patients, 
including Y181C, L74I, V75M and L210W mutations. tMRCA was found to be 1989.8 
for a larger clade and 1997.5 for a smaller clade. Sequences from intravenous drug 
addicts were intermingled with sequences from sexually infected patients, indicating 
frequent exchange of virus between the transmission risk groups. Our data suggests that 
TDR and the transmission patterns between risk groups rate should be monitored 
regularly and prospectively. 
In Paper II, we evaluated the feasibility, sensitivity and specificity of an RT-based 
assay for quantification of HIV. A high correlation (r
2 
= 0.97), agreement (log 
difference = 0.34; 95% CI -0.35;1.03), sensitivity (98%) and specificity (100%) were 
found between the RT-based assay and the Roche Cobas TaqMan. Its feasibility was 
further confirmed in a clinical trial including 605 Vietnamese HIV-1 infected patients. 
Our results show that the RT-based assay is an attractive low-cost alternative for 
monitoring of efficacy of antiretroviral therapy programs in resource-limited settings. 
In Paper III, a simple phenotypic RT-based assay was developed for the detection of 
drug resistance to the 2
nd
 generation NNRTI etravirine (ETR) and cross-resistance 
patterns to the 1
st
 generation NNRTIs. For all recombinant HIV-1 RTs, ETR displayed 
expected IC50 values equivalent to previous reports. The test could detect ETR 
resistance in plasma samples (n=28) obtained from treatment-naïve and experienced 
Swedish HIV-1 infected patients associated with Y181C and L100I substitutions as 
well as discriminate between the impact of K103N on the IC50 value of nevirapine but 
the lack of impact on the IC50 value of ETR. In Paper IV, a further comparison was 
performed between our phenotypic ETR resistance assay and the genotype obtained by 
direct sequencing and ultra-deep pyrosequencing (UDPS) in 20 Swedish patients with 
past or ongoing failure on the 1
st
 generation NNRTIs. Most of the strains from the 
patients had various degrees of decreased phenotypic ETR susceptibility despite 
absence of ETR resistance associated mutations (RAMs) according to direct 
sequencing. Additional resistance mutations corresponding to <20% of the viral 
populations were found by UDPS in 9 analysed patients. In four of these, the mutations 
are likely to have contributed to phenotypic resistance. The patient treatment histories 
and the UDPS data supported that our phenotypic assay may be more sensitive than 
direct sequencing in identifying minor quasispecies with resistance mutations. The 
degree and pattern of an increased assay sensitivity as well as the clinical relevance 
remains to be determined. 
In Summary, since the evaluated RT-based assays are simple to perform, use basic 
laboratory equipment, and does not require complex interpretations, they could be a 
low cost alternative for both studying VL and drug resistance to 1
st
 and 2
nd
 generation 
NNRTIs in LMICs. 
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1 THE HUMAN IMMUNODEFICIENCY VIRUS 
In the beginning of 1981, men who have sex with men (MSM) in the US fell ill from 
opportunistic infections and Kaposi´s sarcoma, a rare form of cancer. The symptoms 
demonstrated clear evidence that the patients suffered from immune suppression and these 
clustered symptoms were named acquired immunodeficiency syndrome (AIDS) [1]. Two 
years later in 1983 it was reported by a French research group [2] that the 
immunodeficiency was caused by a retrovirus, and that target groups were not limited to 
MSM, indeed it was a disease that could affect all. Soon after, an American research group 
also published their findings [3, 4]. Both the French and the American groups noted that 
the virus infected T-lymphocytes, why they named it LAV (lymphadenopathy-associated 
virus) and HTLV-III (human lymphotropic virus type III), respectively. In 1986, the virus 
was renamed human immunodeficiency virus (HIV) [5]. 
Today, almost thirty years after the start of the global HIV/AIDS epidemic, we are still 
unable to control the spread of the virus and during 2011 approximately 34.2 million 
people were estimated to be living with HIV (www.unaids.org).   
There are two types of HIV; type 1 (HIV-1) that was first isolated and type 2 (HIV-2) that 
was discovered in 1986 [6]. The more pathogenic HIV-1 is spread worldwide and is 
responsible for the vast majority of cases of AIDS, whereas the less pathogenic HIV-2 is 
mostly found in the western parts of Africa [7]. HIV is thought to originate from the simian 
immunodeficiency virus (SIV) prevalent in African non-human primates and the passage 
to humans is thought to have taken place in the beginning of the 20th century [8, 9]. HIV-1 
(from now on referred to as HIV) is divided into groups; major (M), outlier (O) and non-M 
non-O (N). The M group is further divided into subtypes A-K which have a distinct 
geographic distribution worldwide, although there is a rapid spread of different subtypes to 
new areas of the world. Occasionally, two viruses of different subtypes “meet” in the cell 
of an infected person and the genetic material from these viruses combine to create a 
hybrid virus. If this “new” strain survives long enough to infect at least two separate 
individuals it is referred to as a “circulating recombinant form”, CRF. 
 
1.1 STRUCTURE AND REPLICATION 
HIV is a spherical particle of approximately 100 nm. The outer envelope is composed of a 
phospholipid bilayer derived from the infected host cell. A schematic presentation of HIV 
is shown in Figure 1. HIV is a lentivirus of the retroviridae family and as such contains its 
genetic information in the form of two single stranded RNA molecules. The viral particle 
also contains viral enzymes used during the replication process. The reverse transcriptase 
(RT) converts the viral RNA to DNA, while the integrase enzyme integrates the new viral 
DNA into the host cell DNA. Two cellular transfer RNA (tRNA) strands are also carried 
within the virion and these act as primers for the reverse transcription carried out by the 
RT. The genome encodes three major genes, env, pol and gag as well as several regulatory 
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and accessory proteins essential for the viral replication. The envelope (env) gene codes for 
the surface envelope glycoproteins (gp120 and gp41). The group specific antigen (gag) 
gene codes for the matrix (MA), nucleocapsid (NC) and capsid (CA) proteins, while the 
polymerase (pol) gene codes for the viral enzymes, reverse transcriptase, protease and 
integrase [10].  
 
 
 
Figure 1. The HIV virion (published under commons, PD-USGov-HHS-NIH) 
 
 
The viral life cycle (see Figure 2) begins by interactions between the viral gp120 and the 
CD4 receptor on the target cells; T-lymphocytes, macrophages, monocytes, dendritic cells 
and microglial cells [11-13]. In addition to the CD4 molecule on the host cell, the virus 
requires either of the co-receptors CCR5 or CXCR4 for entry [14], which triggers a fusion 
between the membranes of the virus and the cell, releasing the viral nucleocapsid into the 
cell.  
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Figure 2. Schematic overview of the HIV replication cycle (published under commons, GFDL-en). 
 
 
Once inside the cell, the viral nucleocapsid undergoes partial uncoating, releasing its 
contents into the cell cytoplasm. The two copies of viral positive single stranded RNA are 
exposed and reverse transcription of the viral RNA to DNA is performed by the reverse 
transcriptase (RT) enzyme. Through RT ribonuclease activity, the DNA strand is removed 
from the RNA strand and a second DNA strand is synthesised. The dsDNA is then 
transported from the cytoplasm into the nucleus of the cell whereafter it is ligated into the 
host chromosomal DNA by the viral enzyme integrase and becomes the proviral DNA 
[15]. However, the RT lacks proof reading, which consequently introduces mutations in 
the provirus and is the source of the high genetic variability of HIV [16, 17]. This is 
beneficial for the virus as it can quickly adapt to the environment in which it replicates and 
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thereby escape the immune system as well as drug pressure. During the reverse 
transcription, long terminal repeats (LTRs) are added to both ends of the DNA and LTRs 
are crucial for facilitating the subsequent transcription of the viral genome. Frequently, 
transcription of the integrated proviral DNA is initiated immediately but in some cells the 
proviral DNA remains latent for a variable length of time until host cell activation, which 
makes it very difficult to clear the viral infection [18]. The transcription of the provirus is 
initiated by cellular factors. Viral mRNA is produced from the provirus by action of a 
cellular RNA polymerase and the resulting mRNA is spliced, and are then transported out 
of the nucleus into the cytoplasm [19]. The mRNAs are translated in the cytoplasm to 
precursor proteins. The viral proteins assemble at the host cell surface where the Env 
proteins, necessary for budding from the host cell membrane, are inserted. Shortly after 
budding, the gag and gag-pol precursors are cleaved by viral protease and new infectious 
virions are produced, ready for the next round of infection [20-22]. 
 
1.2 COURSE OF INFECTION 
HIV may be transmitted by sexual contact, transfer of infected blood and from mother to 
child during pregnancy, birth or breastfeeding. Although the rate of disease progression is 
highly variable among HIV patients, most infections follow a typical course shown in 
Figure 3 that can be divided into three stages: primary infection, chronic infection, and 
AIDS [23]. The primary or acute infection starts shortly after HIV enters the body and the 
high replication of the virus initiates an immune response by producing HIV antibodies 
and cytotoxic T lymphocytes. This stage  that occurs a few weeks after initial infection [24] 
may be accompanied by a flu-like illness. It is characterised by high viral loads [25], 
referred to as the acute phase viremia. After the acute stage of HIV infection the patient 
progresses to the chronic stage which may last for up to ten or more years in untreated 
patients before AIDS develops [26]. 
 
 
 
Figure 3. Course of HIV infection (published under commons, hiv-timecourse.png) 
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1.3 HIV SUBTYPES 
HIV is divided into two different types: HIV-1 and HIV-2. HIV-1 is divided into three 
major groups: group M (main), group O (outlier) and group N (non-M, non-O) [27]. Group 
M dominates the world epidemic and has 10 subtypes (A to K). Sub-Saharan Africa is 
predominated by HIV-1 subtype C, which is causing >50% of the global HIV-1 epidemic 
(Figure 4). Subtype C was first described by our research group in 1990 [28]. 
 
 
 
Figure 4. Global distribution of HIV-1 subtypes 
(Source: http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html) 
 
No strong evidence for differences in clinical outcome or transmission rates have been 
described between subtypes, although such differences have been suggested to be present 
in a few studies [29-31]. A major implication in practice of the genetic differences between 
subtypes is that the precision of molecular based assays such as PCR based assays for 
measuring VL and genotypic resistance testing may be influenced by this genetic variation 
[32]. In addition, when it comes to HIV drug resistance development, the pattern of 
resistance associated mutations may to some extent differ between subtypes although this 
occurs only for a limited number of mutations [33-36].  
 
In Vietnam, which will be described further in Papers I and II, the first documented 
Vietnamese case detected was a subtype B virus [37], but since then the epidemic has been 
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dominated by the recombinant strain CRF01_AE, which is the predominant subtype in 
South-East Asia [38, 39]. 
 
1.4 MOLECULAR EPIDEMIOLOGY 
Vietnam´s HIV epidemic is considered to be one of the fastest growing in Asia and is one 
of the 10 leading causes of mortality in the country [40]. Since the first case was detected 
in 1990, over 50,000 people have died of AIDS and at the end of 2010, there were 254,000 
people living with HIV (PLHIV) [41]. Some provinces have progressed to a generalised 
epidemic with more than 1 % of the adult population infected with HIV, such as Quang 
Ninh, Ho Chi Minh City and Hai Phong (UNAIDS, 2006). 
 
HIV transmission in Vietnam has so far largely been driven by intravenous drug users 
(IDUs) and more recently the spread of HIV in Vietnam increasingly appears to occur 
through sexual transmission [42] which suggests that the epidemic may become more 
difficult to control. In Paper I phylogenetic analyses including molecular clock 
calculations was performed to investigate the HIV transmission patterns in Quang Ninh 
province, Northeastern Vietnam.  
 
A phylogenetic tree is a branching diagram or “tree” showing the inferred evolutionary 
relationships among different species, organisms, or genes from a common ancestor. It can 
be used to study evolutionary relatedness of different organisms or relationship between 
strains of the same organism. Due to the fast evolution of HIV, it is possible to use 
phylogenetic trees for detailed evolutionary and epidemiological studies. The branching-
tree is called the topology and the length of the branches describes their genetic distances, 
which is related their evolutionary time. Calculations of the time of the most recent 
common ancestor (tMRCA) can be done. In Paper I, our study of the Vietnamese samples 
were found to be clustered into two distinct groups; one small clade that had a tMRCA in 
year 1997.5 and a larger group with an estimated tMRCA in 1989.8. 
 
There are different ways of assessing confidence of the branches in the tree. The traditional 
method is called bootstrap analysis, which was used to perform the phylogenetic analysis 
of the strains in Northeastern Vietnam in Paper I. This analysis showed that 100% of 
patients included in the study were infected with HIV-1 subtype CRF01_AE with ≥95% 
bootstrap support.  
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2 DIAGNOSIS AND MONITORING OF HIV INFECTION 
 
2.1 DIAGNOSIS 
The standard way to diagnose a HIV infection is by the detection of antibodies against the 
virus. This test is performed by enzyme linked immunosorbent assay (ELISA), where the 
ability of antibodies present in plasma or serum to bind viral lysate or proteins is 
determined. To confirm that the person is infected, a Western blot or the similar 
recombinant immunoblot assay (RIBA) could be performed. Here, the reactivity of the 
antibodies is determined after separation of the viral proteins by electrophoresis. In the 
positive test the patient serum should react with two or more of p24, gp41, gp120 or gp160. 
In low-middle income countries (LMICs), the diagnosis is made instead by two 
complementary ELISAs, an approach which has a similar precision.  
 
2.2 MONITORING 
In high-income countries, disease progression is monitored by CD4+ T-cell counts, plasma 
HIV RNA levels (“viral load”, VL) and clinical symptoms. In untreated patients, CD4+ T-
cell count is the most important marker indicating level of immunosuppression and hence 
the urgency of initiating ART. In treated patients, measuring HIV RNA levels in plasma is 
the key component for monitoring treatment outcome and/or adherence. A higher VL 
results in a more rapid disease progression in untreated patients [43, 44]. In practice in high 
income countries, both CD4 T-cell count and VL are frequently used for assessing patient 
prognosis [45]. At ART failure and when the virus becomes resistant, this is rapidly 
detected as an increase of the VL. The failure is usually defined as increasing HIV RNA 
levels while being on ART. 
 
Presently (2013) in Sweden and in most high-income countries, Taqman PCR is the assay 
of choice for HIV RNA quantification which has a sensitivity of 20 copies/ml [46]. 
Monitoring is recommended every three to six months in treatment-naïve HIV-infected 
patients, around 4-6 weeks after treatment initiation, and thereafter every three to six 
months, according to the Swedish HIV guidelines [47]. Mostly, the efficacy of ART is 
high with 92% of Swedish patients reaching the aim of undetectable VL with the standard 
techniques in 2012 [48]. In the past a substantial number of patients in high income 
countries failed ART with HIV drug resistance development as a consequence. Presently, 
the number of patients failing ART is limited and hence resistance development is much 
more uncommon than in the past [49].  
 
In LMICs, VL measurement can seldom be done due to high costs, lack of expertise and 
equipment in addition to logistic problems. Instead, the monitoring of ART in most LMICs 
is presently based on clinical parameters and CD4+ T-cell counts, see chapter 4. Therefore, 
there is a need of simpler methods for the assessment of VL in such contexts. In Paper II, 
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it was shown that an ELISA-based method from Cavidi (Uppsala, Sweden), measuring the 
activity of the HIV reverse transcriptase (RT), enzyme is proportional to the VL in the 
plasma [50, 51]. In Paper II, we also compared Roche Cobas TaqMan
® 
with ExaVir Load 
and found a strong correlation (r
2
 = 0.97; p < 0.001) between the two assays.  
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3 HIV THERAPY  
 
3.1 ANTI-HIV DRUGS 
The HIV lifecycle provides several potential opportunities to block viral replication. The 
first antiretroviral drug, zidovudine (ZDV), was introduced in 1987. During the early days 
of the HIV pandemic antiretroviral treatment (ART) was given as a mono-and/or dual 
therapy. This turned out to be a suboptimal strategy that soon resulted in a high degree of 
drug resistance [52-54]. The clinical benefits were not satisfactory and a more potent 
strategy was urgently needed. Today, three or more drugs from at least two different 
classes are used simultaneously to selectively reduce the level of viral replication and 
minimise the risk of developing drug resistance. Combination of ART has dramatically 
decreased mortality and increased the quality of life of HIV-infected individuals [55]. 
 
Today, there are five different classes of drugs used in ART; nucleoside analogue reverse 
transcriptase inhibitors (NRTIs), non-nucleoside analogue reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), integrase inhibitors, and entry inhibitors, all with 
different modes of action.  
 
3.1.1 NNRTI 
In this thesis, the focus is on the NNRTI class and in particular etravirine (ETR). These 
drugs are blocking the activity of the RT by binding into a hydrophobic pocket, located 
close to but not in the active site of the enzyme (Figure 5). The steric interaction of the 
NNRTI makes the RT less flexible and thereby prevents it from further action [56, 57]. 
Five current drugs belong to the NNRTI; efavirenz (EFV), nevirapine (NVP), delavirdine 
(DLV, not approved in EU), etravirine (ETR) and rilpivirine (RPV).  
 
The current Swedish guidelines (updated 2011) for first-line ART in treatment naïve 
patients recommend the use of two NRTIs together with one NNRTI, or two NRTIs and 
one ritonavir-boosted protease inhibitor PI/r (www.rav.nu), and are quite similar in the US 
(Department of health and human services (DHHS), International Antiviral Society-USA 
(IAS-USA) and Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults 
and Adolescents: http://aidsinfo.nih.gov, 2011) and in Europe (The European AIDS 
Clinical Society: www.europeanaidsclinicalsociety.org, 2011). A revised version of the 
Swedish guidelines will be launched in autumn 2013 and the combination of two NRTIs 
together with one NNRTI is likely to still be one of the alternatives for the first line 
therapy.  
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Figure 5. This ribbon representation of the RT active domain illustrates its hand-like structure, showing 
fingers (blue), palm (pink) and thumb (green). The active site (red atoms), where DNA is elongated, is in the 
palm region. Also shown is an NNRTI drug (yellow) in the pocket where it binds (published under commons, 
source http://www.psc.edu/science/madrid2000.html)  
 
3.1.1.1 First generation NNRTI 
NPV and EFV are the first generation NNRTIs that are approved for treatment of HIV 
infection. These drugs are still used frequently in high income countries and are the 
cornerstone in LMICs. In contrast, DLV was not approved in EU and has scarcely been 
used in USA because of side effects. The efficacies of NVP and EFV in combination with 
two NRTIs are good and the major problems are side effects and the low genetic barrier to 
development of HIV drug resistance (see below) [58]. The genetic barrier, defined as the 
number of mutations required to overcome drug-selective pressure, is an important factor 
for the development of HIV drug resistance. Frequently, NNRTIs are used in a fixed dose 
combination, together with NRTIs, as a single tablet regimen in order to enhance the 
convenience and the adherence to the treatment, both in high income countries and LMICs.  
 
3.1.1.2 Etravirine 
ETR is a second generation NNRTI that has been approved for treatment of HIV infection 
in treatment experienced adult patients who are harbouring HIV strains resistant to the first 
generation NNRTIs (EFV and NVP). Thus, in high income countries ETR is frequently 
used together with a boosted protease inhibitor and one or two NRTIs in patients with 
limited treatment options due to HIV drug resistance. ETR shows good activity in vitro 
against most wild-type strains of HIV, as well as against several strains resistant to 
available first generation NNRTIs (EFV and NVP). Furthermore, ETR appears to present a 
higher barrier than first-generation NNRTIs to the development of drug resistance. 
Whereas the presence of a single mutation is sufficient to affect the virological response to 
EFV or NVP, the resistance profile of ETR is more complex. Importantly, the most 
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prevalent NNRTI-associated mutation K103N has been claimed not to affect the ETR 
response alone [59]. However, evidence of ETR cross-resistance is present when multiple 
NNRTI mutations are detected during ART failure [60, 61]. In a study from Thailand, 
approximately 60% of patients failing first generation NNRTI-based ART had a high-level 
of ETR resistance. The role of ETR in second-line therapy may thus be limited in late 
NNRTI failure settings [60] and there is a need for resistance testing in order to identify 
possible candidates for ETR therapy.  
 
3.1.1.3 Rilpivirine 
Rilpivirine (RPV) is also a second generation NNRTI that is approved for treatment of 
HIV infection in NNRTI-naïve patients in most high-income countries. In EU, but not in 
the USA, the indication is to use RPV in treatment-naïve patients with VL less than 
100,000 HIV RNA copies per ml. Thus, RPV is not approved for the use of patients failing 
NVP, EFV or ETR. In addition, there is a very high degree of cross-resistance between 
RPV and ETR [62]. RPV is available as a fixed-dose combination of emtricitabine (FTC), 
rilpivirine (RPV) and tenofovir disoproxil fumarate (TDF). Resistance mutations appears at 
a very low frequency, however when they occurs it is often the E138K substitution in 
combination with the M184I substitution during RPV treatment. 
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4 HIV THERAPY IN LOW-MIDDLE INCOME COUNTRIES 
 
At the end of 2011, 8 million people were receiving ART in LMICs. This is a 26-fold 
increase since 2003. Another 7 million people need to be enrolled in treatment to meet the 
target of providing ART to 15 million people in 2015 [63]. By the end of 2011, 54% of the 
people eligible for treatment were receiving ART. Coverage is highest in Latin America 
(70%) and the Caribbean (67%), followed by sub-Saharan Africa (56%), Asia (44%), 
Eastern Europe and Central Asia (23%) and lowest in the Middle-East and North Africa 
(13%) [64]. 
 
The transmission of HIV from an HIV-positive mother to her child is called vertical or 
mother-to-child transmission (MTCT) [65, 66]. In the absence of any interventions HIV 
transmission rates are between 20-45%. MTCT can be nearly fully prevented if both the 
mother and the child are provided with antiretroviral drugs throughout the stages when 
infection could occur. WHO recommends a range of options for prevention of MTCT 
(PMTCT), which includes providing ARVs to mothers and infants during pregnancy, 
labour and the post-natal period, or offering life-long treatment to HIV-positive pregnant 
women regardless of their CD4 count.  
 
The widespread availability of ART increases the risk for transmission and acquisition of 
drug resistant HIV-1 variants that compromise ART. However, drug resistance testing and 
follow up of the patients in order to retain the disease in the chronic phase and with low 
VL is not equally expanded. Indeed, accumulating data suggest that there is a steady 
increase of HIV-1 drug resistant mutations in patients in LMICs, such as in sub-Saharan 
Africa [67]. A systematic literature review and pooled analysis of data from WHO surveys 
[67] indicate that there is an increasing levels of drug resistance, primarily to NNRTIs. 
 
In LMICs, first generation NNRTIs, EFV or NVP are used as a first-line therapy, most 
frequently together with 2 NRTIs (presently tenofovir or zidovudine and lamivudine). In 
order to enhance adherence and convenience as well as save costs the treatment is 
frequently given as fixed dose regimen in single dose tablets. Resistance to first generation 
NNRTIs as well as to NRTIs is an increasing problem in the treatment of HIV-1 infected 
patients in LMICs [68-70]. Access to other drugs varies in different LMICs. Frequently 
alternatives to the first line regimen are limited to a few drugs although there is an 
increasing use of ritonavir-boosted protease inhibitors such as lopinavir/r. Presently, no 
studies on the use of second generation NNRTIs in LMICs have been published. However, 
studies from India and Thailand have shown that there is a risk for cross-resistance to ETR 
if several NNRTI mutations have developed [60, 61, 71]. 
 
To ensure the sustainability of ART programs in LMICs, it is of great importance to 
maintain patients on first-line regimens as long as possible. In high income countries VL 
 13 
measurement is a standard for monitoring the effectiveness of ART. However, virological 
monitoring is not widely accessible among LMICs due to high processing cost and 
requirement of advanced equipped laboratory. LMICs have been encouraged by the WHO 
to increase access to VL testing. For clinical decision making related to switching drug 
regimen, virologic failure has been defined as >5,000 copies/ml [72]. In the absence of 
VL, the recommendations are to use clinical symptoms or CD4 cell count [73]. However, 
relying only on CD4 cell count assessment is neither sensitive nor specific for virologic 
failure [74-76], increasing the risk of viremia going unnoticed and the emergence of drug 
resistance. In high-income countries, viremic patients on treatment are assessed routinely 
for the presence of drug resistance mutations (DRMs) by genotypic or phenotypic 
resistance testing [77, 78]. A low-cost tool for assessing drug resistance and sustain use 
of the first-line regimen in LMICs is therefore needed [72, 79, 80]. In Papers III and IV, 
a technically simpler and cheaper cost method (see chapter 6) for monitoring resistance 
to ETR are described compared to the traditional drug resistance test. Other ways of 
maintaining an efficacious treatment could be to switch treatment at a pre-specified point 
based on the predicted pattern of drug resistance development [81].  
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5 HIV DRUG RESISTANCE 
 
5.1 MECHANISM OF HIV DRUG RESISTANCE 
HIV is characterised by its high genetic diversity. First, this high diversity is a result of the 
high levels of virus production and turnover. Second, HIV has a very high rate of 
nucleotide sequence evolution which in turn is due to the high error rate of the viral reverse 
transcriptase. This leads to the generation of many variants of HIV in a single infected 
patient. The swarm of genetic viral variants is called quasispecies, which may allow the 
virus to escape from the immune system as well from ART [82]. Viruses with mutations 
that result in a fitness advantage will outgrow other variants and become the dominant viral 
population among the quasispecies. Under continued drug pressure but with concomitant 
therapy failure, viral quasispecies with reduced drug susceptibility accumulate with time, 
but when the treatment stops, VL will increase and wild-type virus takes over due to its 
greater replicative capacity [83]. The drug resistant variants usually have reduced fitness 
compared to wild-type virus. This is especially true for viruses with single primary 
resistance mutations. In contrast, additional mutations, which may evolve over time during 
continued drug selective drug pressure, may compensate, thus restoring fitness to near 
wild-type levels. The rate of drug resistance depends on patient adherence to treatment, the 
genetic barrier, host genetics, and fitness of the drug resistant variant [84, 85]. 
 
5.2 ACQUIRED HIV DRUG RESISTANCE 
In treated patients, drug resistance associated mutations can be acquired when virus 
suppression is not completely achieved and replication of the virus can continue at low 
levels. The genetic barrier, defined as the number of viral mutations required to escape 
from the selective pressure of the drug, is an important factor for the development of drug 
resistance [86-88]. Boosted PIs for example have a high genetic barrier as they require 
multiple (3-5) mutations to overcome the drug pressure [86, 88]. Conversely, several other 
drugs have a low genetic barrier as a single mutation is sufficient for viral breakthrough, 
including first generation NNRTIs (nevirapine, efavirenz), 3TC/FTC and first generation 
integrase inhibitors (raltegravir, elvitegravir) [86, 88]. Many mutations selected by the use 
of one drug also cause cross-resistance to other drugs of the same drug class, limiting 
further treatment options. Often, viruses with major resistance mutations have reduced 
replication rates. This can be compensated by compensatory mutations that emerge after 
the major mutations. They do not reduce drug susceptibility, but improve the replication of 
the virus. 
 
5.3 TRANSMITTED HIV DRUG RESISTANCE 
Viruses with resistance mutations can be transmitted to other individuals. Because wild-
type virus is rarely co-transmitted together with the drug-resistant HIV, the quasispecies 
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have no “memory” of the wild-type [89]. There are three possible evolutionary pathways 
for this transmitted drug-resistant variants described. First, when there is a profound effect 
on the replication rate of the virus, the resistant variant may revert back to wild-type. 
Second, atypical variants may be observed when it results in higher replication rate than 
the original transmitted resistant variant. Finally, the resistant variant can persist. Mutations 
that induce only a limited decrease in the replication rate tend to persist. Furthermore, in 
patients experiencing treatment failure, multiple compensatory mutations may appear after 
the initial selection of resistance mutations that lower the replicative capacity. After 
transmission to a new host, evolution may be expected to occur in a stepwise manner. 
However, if all possible nucleotide changes would initially decrease the replicative 
capacity, reversion to wild-type will be blocked [90]. 
 
5.3.1 MINOR POPULATIONS 
The non-dominating populations among the quasispecies are called minor populations. A 
possibility is that a minor population which evolves independently of the major population 
can eventually emerge as the dominating population, thereby serving as a reservoir of 
diversity and possibly accelerating the development of drug resistance [91, 92]. This could 
happen under drug pressure either because it had developed higher resistance or because of 
a change in drug pressure that gave the minor population a growth advantage over the 
major population. Possibly, minor populations can represent vestiges of previously 
dominant populations or earlier stages of HIV evolution or alternatively originate from 
tissue compartments with lower drug concentrations and consequently reduced drug 
pressure [92].  
 
5.3.2 HIV DRUG RESISTANCE TESTING 
Antiretroviral drug resistance testing has become an important tool in therapeutic 
management of HIV-1 infection in high-income countries. There are two categories of 
methods available for resistance testing, genotypic and phenotypic.  
 
5.3.2.1 Genotypic assays 
The genotypic way to determine resistance is to search the gene of interest for mutations 
known to be associated with reduced drug susceptibility [93]. Population based sequencing 
of the pol gene including regions encoding RT, protease and/or integrase is generally 
generated by in-house methods or by commercial assay such as ViroSeq from Abbott. The 
sequences can be used for online prediction at Stanford University HIV Drug Resistance 
Database (http://hivdb.stanford.edu). The cost of a genotypic assay is much less than the 
price of a typical phenotypic test but still expensive for LMICs. Furthermore, the genotypic 
assay is performed more rapidly, while for a phenotypic assay a longer time is needed. 
Therefore, the genotypic test is the preferred test in clinical practice and is recommended 
by the European HIV Drug Resistance Guidelines Panel [94] and the International AIDS 
Society-USA Panel [95]. However, genotypic testing is challenging due to the complexity 
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of interpreting the many different drug-resistant mutations and translating these mutations 
into treatment response. All interpretations of genotypic data are based on phenotypic data 
about which mutations give rise to reduced drug susceptibility. Several interpretation 
systems have been developed, providing rules to help physicians interpret genotypic 
results. Another more advanced approach has been developed based on large HIV clinical 
databases and bioinformatics methods. These databases contain information about clinical 
status, demographics, HIV RNA, CD4 T-cells levels in addition to viral sequences. By 
bioinformatics analysis an improved prediction of which drug combinations are best suited 
to use after treatment failure is obtained as compared to established interpretation systems 
based on genotype sequence analysis only [96-99].  
 
Another problem with today´s routine HIV genotyping methods, is that these techniques 
are not sensitive enough to detect viral populations that represent less than 20-25% of the 
total population [100-102], likely underestimating minor populations that may play a role 
in drug resistance development. Several methods to detect and quantify minor populations 
of drug resistant HIV have been described during recent years [103]. One of them is the 
allele-specific real-time PCR (ASPCR) [102-104], which allows detection of minority 
quasispecies with a sensitivity of down to 0.01% for certain mutations, however one or 
only a few mutations at a time can be analysed. Another alternative to be able to detect 
minor populations could be to use the next generation sequencing (NGS) technologies. The 
population based Sanger method [105] used today for routine HIV genotyping is 
considered as a “first generation” technology, and dominated the sequencing field for about 
two decades prior to the development of NGS [106].  
 
5.3.2.1.1 Ultra-deep pyrosequencing (UDPS) 
The high throughput of NGS technologies, generating million of sequence reads in a short 
time, makes them suitable for sequencing of whole genomes, such as human, bacteria and 
plants. In this sequencing, short sequence reads are generated from fragmented DNA. The 
reads are aligned to a known reference sequenced or assembled de novo. Due to the length 
of the reads, 454 sequencing has an advantage for deep sequencing projects, referred to as 
ultra-deep pyrosequencing (UDPS). UDPS allows identification of rare genetic variants, 
which are not detectable by population based Sanger sequencing [107-110]. The depth of 
the UDPS analysis is primarily determined by the number of templates that can be 
successfully extracted and amplified from the starting material and by the error rate of PCR 
and UDPS. In Paper IV, UDPS was used to identify additional NNRTI resistance 
associated mutations (RAMS) in minor populations. 
 
5.3.2.2 Phenotypic assays  
The phenotypic assays are based on determination of the ability of virus representing the 
patient´s phenotype to grow in culture together with the drug at different concentrations 
[111, 112]. The classical approach was to isolate virus from patient cells, and infect a cell 
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culture with these in the presence of various concentrations of a drug and estimate the 
ability of the cultures to produce virus [113]. Except for the very long time required for 
such an assay, this handling is prone to introduce artefacts from the virus propagation, such 
as selection of irrelevant virus due to the artificial conditions in the culture.  
 
Later recombinant methods have been developed [111, 112, 114], of which some are 
commercially available. These are based on PCR amplification of the patient pol gene (RT 
and PR) from virus isolated from a patient, and creation of a recombinant virus including 
the amplified pol gene. This recombination virus is then assayed for drug susceptibility in 
culture. The raw data output is the concentration of drug required to inhibit viral replication 
by 50% or 90% (IC50 or IC90, respectively) relative to the control. Results as usually 
expressed as the IC50 of the drug being tested for the patient-derived virus divided by the 
IC50 for the reference virus. The value of this ratio is commonly referred to as a fold change 
in susceptibility used the drug concentration that inhibits the viral replication by 50%, 
compared to reference recombinant wilt-type virus as demonstrated in Figure 6.  
 
 
Figure 6. Phenotypic drug susceptibility curves. The continuous curve represents a wild-type drug-
susceptibility virus. The shift to the right of the dashed curve, representing a strain isolated from a patient, 
indicates a reduction in drug susceptibility to a higher IC50 value. (Published under public domain, source: 
http://www.ncbi.nlm.nih.gov/books/NBK2254/#A403). 
 
The interpretation of phenotypic data is based on the measurement of the fold change for 
each antiretroviral drug tested against pre-defined cut-offs. The first important issue related 
to phenotype interpretation is determining the appropriated cut-offs for defining a clinical 
isolate as either drug susceptible or drug resistant. Until, recently technical cut-offs were in 
use, based on the reproducibility of the assay on repeat testing. One improvement over 
technical cut-offs was the introduction of biological cut-offs, which are based on the 
distribution of the drug susceptibility of isolate from thousands of treatment-naïve patients 
[115]. 
 
For interpretation of phenotypic data based on biological cut-off, the clinical isolate is 
usually scored as susceptible to a certain drug if the fold change falls within the mean fold 
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change observed with samples from treatment-naïve patients, plus two standard deviations. 
A test result falling above cut-off can be said to be above the normal susceptible range. 
This provides a reference for comparison of the test with viruses circulating in the drug-
naïve population, although it does not provide information about the likelihood that the 
virus tested will respond to treatment with a particular drug. Thus, neither technical cut-
offs nor biological cut-offs provide a link between drug susceptibility measured in vitro 
and the virological response observed in vivo. 
 
From a clinical perspective, the most relevant method of interpretation of phenotypic data 
is based on the use of clinical cut-offs. These are derived from clinical response data from 
treatment-experienced patients by determining the relationship between fold changes 
measured at baseline and the reduction in viral load after a defined period of treatment. 
Reliable determination of a clinical cut-off requires large sets of clinical data. This, in 
addition to the difficulty in extrapolating the activity of individual drugs within the context 
of combination therapies, are important obstacles to the determination of clinical cut-offs. 
Despite these difficulties, a number of clinical cut-offs have been proposed and are 
currently in use in commercially available phenotypic assays [116-118]. 
 
Because these phenotypic assays are time consuming, expensive and require specialised 
laboratory facilities, they are not widely used as clinical assays in Europe or in LMICs. 
Neither are genotypic resistance assays an alternative to use in LMICs because of the high 
cost and needs for expensive equipment and expert clinicians to interpret genotypic results.  
 
Another alternative could therefore be to determine the phenotypic virus drug susceptibility 
at the RT enzyme level by using a phenotypic method [119-121]. Drug susceptibility 
testing on RT offers advantages compared with traditional phenotypic susceptibility tests 
as they are fast, technically simple and the results are not affected by the metabolism of 
cells used for virus culture in traditional phenotypic assays. In contrast with the results 
from genotypic assays, phenotypic methods do not require complex interpretations.   
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6 RT ASSAYS FOR VL QUANTIFICATION AND RESISTANCE 
TESTING 
RT activity is a unique characteristic of all retroviruses since they need to convert their 
RNA genome to DNA in order to be incorporated into the host genome. Therefore, 
measurement of RT activity has the ability to provide an analytic tool to determine the viral 
replication in HIV. The RT uses the viral RNA genome as template to produce viral DNA 
prior to integration in to the host cell genome. This process can be measured in vitro using 
RNA template and a dNTP analogue (such as BrdUTP) together with colorimetric product 
[122-124], see Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________ 
The RT in the lysates Alkaline phosphatase Colorimetric alkaline phosphatase 
will synthesise a DNA- conjugated antibodies substrate will give a yellow colour, 
strand.  will bind to the DNA/RNA- proportional to the amount product, 
  product.  i.e. the viral load. 
 
Figure 7. Schematic representation of the RT reaction and product detection. (Permission to reprint from 
Cavidi). 
 
6.1 RT QUANTIFICATION 
A methodology for quantification of HIV load based on ELISA methodology has been 
developed [125, 126]. It uses the HIV RT enzyme purified from patient plasma samples to 
catalyse the conversion of RNA to cDNA. The procedure consists of two main parts: the 
separation step for viral RT isolation (Figure 8a and 8b) and the reverse transcription step 
for quantification of the RT (Figure 7). First, the plasma is treated to inactivate cellular 
enzymes and the virus particles are then separated from the plasma by using a gel that 
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binds the virions. The immobilised virions are washed to remove inhibitors, including 
ARV drugs or RT-blocking antibodies. Virions are lysed to obtain the RT and the lysates 
are then transferred to a 96-well plate for assay of RT activity. In an overnight incubation, 
RT enzyme in the lysate incorporates BrdUTP into DNA strand complementary to the 
polyA template (bound to the wells) (Figure 7). Subsequently, an anti-BrdU antibody 
conjugated to alkaline phosphatase is added and the amount of incorporated BrdU is 
detected using a colorimetric substrate. The reaction plate is read at three time points by a 
standard plate reader at wavelength 405 nm. The first reading is the zero reading at 10 
minutes, the second at 2 to 3 hours, and the third on the following day (16 to 24 hours) to 
ensure that small amounts of RT enzyme can be detected. Results are compared to a 
standard curve and the ExaVir Load Analyser software version 3.0 automatically converts 
the amount of RT in femtograms per milliliter (fg/ml) plasma to equivalent RNA copies 
per milliliter of plasma (copies/ml). The analytical sensitivity is 1 fg/ml. The measuring 
range is dependent on the duration of the RT assay and the performance of the plate reader 
used, but in these studies (Papers III and IV) it was typically 1 to 3,000 fg/ml, equivalent 
to 200 to 410,000 copies/ml.  
 
Separation of RT 
______________________________________________________________________ 
The plasma treatment Additive is a The Separation Gel is an ion- As vacuum is created the plasma  
reducing agent that will exchange gel that immobilises remainings will pass through the column. 
inactivate any cellular polymerases the HIV particle by binding to The filter will stop the gel, with the virions  
present in the plasma. the lipid membrane of the virion. bound to it, from going through. 
 
     Illustration: Cavidi AB 
Figure 8a. Procedure for viral RT isolation in the ExaVir
®
 Load. (Permission to reprint from Cavidi). 
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Separation of RT (cont.) 
______________________________________________________________________ 
Gel Buffer 1 removes agents that can 
disturb the RT-assay, like antibodies and 
ARVs. 
Gel Buffer 2 creates a suitable 
environment for the RT. 
The Lysis Buffer breaks the virion open 
and the contents (RT) is released. The 
lysate is collected for an analysis in the RT 
assay. 
       
     Illustration: Cavidi AB 
Figure 8b. Separation of reverse transcriptase (continued). (Permission to reprint from Cavidi). 
 
6.2 VIRAL PHENOTYPIC RESISTANCE TESTING 
With available lysate containing purified RT from the patient plasma, the possibility for 
direct characterisation of RT activity arises. This allows for assessment of acquired or 
transmitted HIV drug resistance. Therefore a phenotypic resistance testing assay based on 
the RT enzyme was developed [127]. The principle of drug susceptibility determination is 
very similar to the above mentioned procedure of RT quantification described in chapter 6 
and 6.1. The RT purified by the above described separation step is assayed together with a 
serial dilution of the ARV drug in the RT-assay described above. The enzymes incorporate 
BrdUMP to different extents depending on the susceptibility to the drug. From the 
inhibition obtained from the different drug concentrations, a profile of susceptibility of the 
RT is obtained, and an IC50 value is calculated. By comparison of the profile with those of 
wild-type and resistant standard RT, the level of resistance in the sample can be assessed. 
The methodology has earlier been evaluated for the NNRTIs EFV and NVP [127, 128].  
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7 NNRTI RESISTANCE ASSOCIATED MUTATIONS 
Resistance to the first generation NNRTIs generally results from a single amino acid 
substitution such as the key mutations K103N or Y181C [129, 130]; this is refered to as 
low genetic barrier. These NNRTI resistance mutations frequently cause cross-resistance 
between EFV and NVP. Single nucleotide changes associated with NNRTI resistance can 
result in high-level resistance with only a slight loss of fitness [131, 132]. In practice a full 
cross-resistance is expected between NVP and EFV after failing therapy with concomitant 
resistance development. Table 1 demonstrates mutations associated with NNRTI drug 
resistance. 
 
ETR appears to present a higher genetic barrier than the first-generation NNRTIs against 
the development of drug resistance. Results from selection experiments with wild-type 
HIV performed at high and low multiplicity of infection showed that at least two mutations 
are required for the development of ETR resistance compared with only a single mutation 
for a first-generation NNRTI [133]. The selection experiments identified the known 
NNRTI resistance-associated mutations (RAMs) L100I, Y181C, G190E, M230L and 
Y318F and the novel mutations V179I and V179F to be associated with development of 
ETR resistance [133]. Furthermore, the impact of individual mutations on resistance was 
highly dependent on the presence of specific co-existing mutations.  
 
Importantly, the presence of the mutation K103N, commonly conferring resistance to the 
first-generation NNRTIs, has been claimed not to cause a loss of virological response to 
ETR. Full cross-resistance is however expected between the second generation NNRTIs, 
ETR and RPV.  
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   L K K V V   Y Y G  P   
Efavirenz   100 101 103 106 108   181 188 190  225   
   I P N M I   C L S  H   
     S     I  A     
                 
 V A L K  V  E V Y  G    M 
Etravirine 90 98 100 101  106  138 179 181  190    230 
 I G I* E  I  A D C*  S    L 
    H    G F I*  A     
    P*    K T V*       
        Q         
                 
   L K K V V   Y Y G     
Nevirapine   100 101 103 106 108   181 188 190     
   I P N A I   C C A     
     S M    I L      
           H      
                 
    K    E V Y   H  F M 
Rilpivirine    101    138 179 181   221  227 230 
    E    A L C   Y  C I 
    P    G  I      L 
        K*  V       
        Q         
        R         
 
Table 1.  Mutations associated with NNRTI drug resistance. Amino acid abbreviations: A, alanine; C 
cysteine; D, aspartet; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, 
leucine; M,methionine; N, asparagine; P, Proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; 
W, tryptophan; Y, tyrosine. Gene positions and corresponding amino acid substitutions marked in bold type 
indicate a high impact on susceptibility and mutations with a lesser impact on susceptibility are represented in 
plain (non-bold) type. Figure adapted from [134]. 
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8 AIMS OF THE STUDY 
 
The aims of this thesis were to develop and/or evaluate assays for monitoring HIV 
treatment of relevance for the situation in low-middle income countries. More specifically, 
I studied simple reverse-transcriptase based assays for the determination of the HIV load 
and drug resistance to non-nucleoside RT inhibitors (NNRTI). These aims were achieved 
by:  
 analysing HIV-1 from treatment-naïve Vietnamese patients by direct sequencing and 
phylogenetic analysis (Paper I) 
 evaluating and implementing a simple RT-based assay for quantification of HIV in a 
Vietnamese cohort (Paper II) 
 developing a simple phenotypic assay for detection of resistance to the new NNRTI 
etravirine (ETR) and to describe cross-resistance patterns between ETR and the first 
generation NNRTIs (Paper III) 
 evaluating the phenotypic resistance assay in relation to sequence data obtained by 
direct sequencing and ultra-deep sequencing (Papers III and IV)  
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9 MATERIAL AND METHODS 
 
For detailed information about material and methods as well as statistical analyses used in 
this thesis, see the respective papers. In brief, the following methods were used: 
 
In Paper I, viral RNA was isolated using QIAamp ViralRNA kit (Qiagen). cDNA was 
synthesised using Superscript III First-Strand Synthesis Supermix (Invitrogen). A product 
spanning protease and the first two-thirds of reverse trancriptase gene of HIV-1 pol-gene 
was amplified. PCR-products were purified using QIAquick PCR-purification kit (Qiagen) 
and sent to Eurofins MVG Operon, Ebersberg, Germany for sequencing. Sequences were 
aligned and edited using the BioEdit and ReCall software. Genotypic resistance analyses of 
all sequences were performed using the Stanford HIVdb Sequence Analysis. Subtype 
classification was done using the REGA HIV Subtyping tool. Phylogenetic analyses were 
performed in BEAST v1.6.1 and tMRCA calculations were done. 
 
In Paper II, quantification of HIV was done using ExaVir
®
 Load version 3 and the princip 
behind this assay are described in chapter 6. Quantification of HIV RNA was performed by 
Cobas
®
 AmpliPrep/Cobas
®
 TaqMan
®
. A Spearman´s rank correlation coefficient (r) was 
calculated, along with 95% confidence intervals for the correlation between HIV RT 
activity and HIV RNA. Bland-Altman plot was used to calculate the agreement of these 
two assays. 
 
In Paper III, RT mutants were produced using the QuikChange site directed mutagenesis 
method (Stratagene). Purification of HIV-1 RT from plasma was done by using ExaVir
®
 
Load version 3 followed by determination of drug susceptibility of RTs towards ETR, both 
described in chapter 6. The genotype was determined by standard GRT. 
 
In Paper IV, purification of HIV-1 RT from plasma was done by using ExaVir
®
 Load 
version 3 followed by determination of drug susceptibility of RTs towards ETR, both 
described in chapter 6. The genotype was determined by standard GRT and UDPS was 
performed in nine of the samples. 
 
9.1 ETHICAL CLEARANCE 
The studies included in thesis were performed after approval from the Regional Ethical 
Committees at Karolinska Institutet. For Papers I and II, Dnr: 2006/1367-31/4, Hanoi 
Medical University Review Board (HMURB) in Bio-medical Research (No. 59/HMURB) 
and the Hanoi Medical Institutional Review Board (IRB) in Bio-medical research Ethics 
(No. 26/IRB). For Papers III and IV, Dnr. 2005/1167-31/3 and 2005/772-31/4. All 
subjects included gave their informed consent to prior study. 
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10 RESULTS AND DISCUSSION 
 
The focus of this thesis was to develpe and/or evaluate assays for monitoring HIV 
treatment of relevance for the situation in low-middle income countries.  
 
10.1 PAPER I 
Study background 
In this study, baseline samples from 63 ART-naïve Vietnamese HIV-patients were 
analysed to assess the prevalence of transmitted drug resistance mutations (TDRM). 
Phylogenetic analyses was also performed including molecular clock calculations in order 
to investigate HIV transmission patterns in Northern Vietnam. All patients belonged to the 
cluster randomised controlled trial “Directly Observed Therapy for Antiretrovirals” 
(DOTARV), registration number NCT01433601, including 640 patients from the 
following districts/cities: Ha Long, Uong Bi, Dong Trieu, Yen Hung. This trial was 
conducted between July 2007 and November 2011, with two years of patient recruitment 
and two years of follow up.  
 
The samples used were collected between December 2008 and January 2009 and genotypic 
analyses of 63 pol-gene sequences were performed using Stanford HIVdb Sequence 
Analysis, (http://sierra2.stanford.edu/sierra/servlet/JSierra?action=sequenceInput) [135]. The 
detected resistance mutations were compared against the TDRM surveillance list [136] as 
well as the IAS-USA 2010 update [137]. Subtype classification was performed using 
REGA HIV Subtyping tool [138]. 
 
Results and discussion 
Drug resistance mutations in ART-naïve patients 
All patients were found to be infected with HIV-1 subtype CRF01_AE with ≥95% 
bootstrap support. In the 63 ART-naïve individuals, most viruses were found to be fully 
susceptible to all protease and reverse transcriptase inhibitors: in 39 (61.9%) sequences we 
found no resistance associated mutations at all, while 20 sequences (31.7%) had one or two 
polymorphic mutations that frequently occur in untreated patients. Four patients were, 
however, infected with viruses carrying resistance mutations, giving a TDRM prevalence 
of 6.3%. An overview of all detected resistance associated mutations is shown in Table 2.   
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Number of patients (%) NRTI mutations NNRTI mutations PI mutations 
1 (1.6) L210W None None 
1 (1.6) L74W None L10I 
1 (1.6) V75M None None 
1 (1.6) None Y181C L10I 
1 (1.6) None A98G None 
2 (3.2) None V179D None 
2 (3.2) None V106I None 
7 (11.1) None V106I L101I/V 
9 (14.3) None None L101I/V 
38 (60.3) None None None 
63 (100)    
 
Table 2. Number of patients with different resistance associated mutations.Mutations on the TDRM list 
(Bennett, 2009) are shown in bold text. Minor resistance mutations present on the IAS-USA list are shown in 
regular format. 
 
Three of the TDRMs present in the analysed samples confer reduced susceptibility to 
NRTIs; L74I (n=1) and V75M (n=1) both confer low-level resistance to ddI (both), d4T 
(V75M) and ABC (L74I), while L210W (n=1) causes a low-level of resistance to all 
NRTIs except 3TC and FTC. The fourth TDRM was Y181C (n=1), which provides 
intermediate to high level of resistance to all NNRTIs. Minor mutations found for reverse 
transcriptase were: A98G (n=1), V179D (n=2), V106I (n=9), while L10I/V was found in 
the protease region of 18 sequences. No clinically significant resistance mutation for 
protease inhibitors were found. 
 
Phylogenetic relationships and tMRCA calculations 
The 63 pol-sequences were aligned with 190 CRF01_AE and four subtype B sequences 
retrieved from public and local databases. The initial analysis in BEAST revealed three 
clearly demarcated clades which all had a posterior probability support = 1. These defined 
three taxons that were used for the subsequent the most recent common ancestor (tMRCA) 
calculations; ‘CRF01_AE’ (which included all the Vietnamese samples plus the 190 
CRF01_AE reference sequences), ‘Vietnam large clade’ (60/63 Vietnamese strains in this 
study), and ‘Vietnam small clade’ (three Vietnamese samples that clustered separately 
from the others) (Figure 9).   
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tMRCA, 
CRF01_AE 
tMRCA, Vietnam 
small clade 
Subtype B 
Thai/Asia 
Origin of sequences: 
Green=Vietnam (this study) 
Orange=Vietnam (other studies) 
Cyan=Thailand 
Light blue= Asia except Thailand and 
Vietnam 
Pink=Africa 
Purple=Europe, USA and Russia 
Blue=Subtype B reference strains 
1974                           1979                          1984                          1989                           1994                          1999                          2004                         2009 
tMRCA, Vietnam large clade 
 
Figure 9. Phylogenetic trees showing the nodes used for tMRCA calculations and the mixture of strains from 
intravenous drug users and sexually infected patients in Northern Vietnam. The small inset tree shows all 257 
strains with the Vietnam large and small clades encircled. In the larger tree some clades have been collapsed 
for clarity. The branch length corresponds to the year of sampling. Node markings: red circles, posterior 
probability > 0.99; blue circle, posterior probability > 0.90. Tip markings: filled circles, intravenous drug 
users; open circles, sexually infected patients. No tip marking, unknown mode of transmission. 
 
Previous studies of the CRF01_AE epidemiology in Vietnam have shown that HIV was 
first introduced in the southern part of the country. By 1993, over 950 infections had been 
diagnosed in Vietnam, of which only three cases were found in the north [139]. The 
introduction of HIV-1 CRF01_AE in Vietnam has been estimated to have occurred at least 
a decade prior to the first detections of clinical cases and by the late 1980´s the disease is 
believed to have spread among IDUs in South Vietnam and thereafter to IDUs in the 
northern part of the country around 1993-1994 [140]. Our results from the clade currently 
spreading through sexual and intravenous transmission in Northern Vietnam date the 
tMRCA a few years prior to this, around 1990. Vietnam large clade includes samples from 
Ha long, Uong Bi, Dong Trieu and Yen Hung from the current study (n=60), as well as 
sequences form Hai Phong [141], Bac Giang and Hai Duong [140] also located in the 
coastal North-Eastern part of Vietnam (n=22), plus a number of intermixed strains from 
China and the Czech Republic (n=13). The tMRCA for the North Vietnam cluster 
calculated by Liao et al (2010) [142] was based on a smaller number of samples (8 
Vietnamese + 2 Chinese samples), which explains discrepancy between these studies. 
Indeed, six of these strains were included in the current study and the tMRCA of these 
strains fell around 1993-1994 (Figure 9, Vietnamese strains sampled 1998). It is therefore 
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likely that larger sampling rather than methodological differences accounts for the different 
time estimates, and that HIV first spread to Northern Vietnam around 1990 or earlier. 
 
The Vietnam small clade has an estimated tMRCA around 1997, but since the number of 
strains is small it is difficult to say whether they represent an emerging cluster in the north 
or if the three infections were unrelated. BLAST searches confirmed that these strains were 
more similar to samples from southern Vietnam (Ho Chi Minh City, An Giang) and 
Thailand than to North Vietnamese and Chinese CRF01_AE strains. One of these samples 
originated from a truck driver, who had travelled widely throughout Vietnam in this job, 
and the other two samples came from women who were/had been married to drivers. It is 
therefore possible that these strains were independently introduced from the southern part 
of the country. None of these genetically divergent strains carried TDRMs. 
 
The Vietnam samples analysed in this study originated from four clinics in the Quang Ninh 
province in Northeastern Vietnam, near the border to China. These clinics are all located 
within a radius of approximately 35 km, and no local clustering was found for the 
respective sites. Twenty-nine samples originated from patients with a history of 
intravenous drug use, 27 individuals were infected through sexual transmission and the 
mode of transmission for the remaining seven patients was unknown. Samples from 
patients with different modes of infection were completely intermixed in the phylogeny 
(Figure 9) indicating that HIV-transmission frequently occurs between intravenous drug 
users and non-drug users in northern Vietnam. 
 
10.2 PAPER II 
 
Study background 
In this study we analysed the feasibility of the RT-based ELISA method for quantification 
of HIV in monitoring virologic outcome and ART efficacy. We also compared the RT-
based method with Cobas TaqMan PCR. 605 ART-naïve patients from the study cohort for 
directly observed therapy with antiretrovirals (DOTARV) were included. The details of the 
Vietnamese cohort and the clinical outcome of the treatment are described in detail in 
Paper I. 
 
From the total number of patients (640) in the cohort, 35 (6%) patients were excluded due 
to being non-naïve. Intention to treat analysis was applied to estimate treatment outcomes 
(mortality, virologic suppression rate, and virologic failure rate). Survival analysis was 
used to study the time from the start of ART to “virologic failure”, defined as VL >1000 
copies/ml, Kaplan-Meier estimations of the survival curve and Log-rank tests are 
presented, stratified by baseline VL. 
 
Also a total of sixty plasma samples were randomly selected for a comparative study and 
quantified with both ExaVir Load version 3.0 (described in chapter 6) and Cobas TaqMan 
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PCR version 2.0 (detection limit <40 copies/ml). ExaVir Load was performed at Uong Bi 
General hospital according to the manufacturer´s instructions and Roche Cobas TaqMan 
PCR was performed at the Bach Mai Hospital in Hanoi according to manufacturer´s 
instructions.  
A Spearman´s rank correlation coefficient (r
2
), along with 95% CIs was calculated for the 
correlation between HIV RT activity and HIV RNA. In addition, we used a Bland-Atman 
plot to calculate the agreement of these two assays. 
 
Results and discussion 
Evaluating the RT assay in the Vietnamese cohort  
A key component in the study was the use of VL quantifications through ExaVir Load. 
Since our study was the largest prospective study in which this methodology was used we 
needed to evaluate the precision in the Vietnamese setting.  
 
Initially, we quantified 60 samples with both ExaVir Load and TaqMan PCR of which 44 
(73%) had detectable virus. A good concordance was found between the methods. The 
median VL was 36,025 (IQR 200-165,770) copies/ml by ExaVir and 74,900 (IQR 41-
208,000) copies/ml by Taqman. There were 15 samples (25%) with undetectable VL by 
both assays, from 16 treated patients. One sample showed a VL of 45 copies/ml by 
TaqMan but an undetectable VL by ExaVir Load. Thus, the sensitivity of the ExaVir Load 
assay relative to the TaqMan PCR was 98%  (44/45) and the specificity was 100% (15 of 
15 patients with TaqMan VL <40 copies/ml had undetectable RT activity). 
 
The Spearman coefficient of correlation was r
2
 = 0.97 [95% CI (0.95 – 0.98); p <0.0001], 
(Figure 10). There was a good agreement between two assays with a mean of difference in 
log VL of 0.34 [95% CI (-0.35; 1.03)] (Figure 11).  
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Figure 10.  Correlation between Roche TaqMan and Cavidi ExaVir Load assays. Undetectable values are 
scored as 40 copies corresponding to the lower limit of RNA quantification. The Spearman correlation 
coefficient was r
2
 = 0.97 (95% CI 0.95–0.98, p <0.0001). The equation for the regression line is log ExaVir 
Load = 0.8931 log TaqMan + 0.1773 
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Figure 11. Bland – Altman plot analysis to compare between Roche TaqMan and Cavidi ExaVir Load 
assays. The mean of difference in log VL results between two assays was 0.34 [95% CI (-0.35 ; 1.03)].  
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Results of VL testing in the clinical study 
Analysis of the VL using ExaVir Load was carried out in a total of 2408 samples of 605 
patients. A detailed description of the virological treatment results are described in Paper 
I. When analysing the 605 ART-naïve patients, after 24 months, 35 (5.8%) patients 
developed virologic failure, of which 15 (43%) were primary virologic failure (VL did not 
become undetectable after 6 months of ART). The cumulative virologic failure rate among 
samples assessed with VL during 24 months was 6.8% (95% CI 4.9-9.3). In patients with a 
high VL at baseline (>100,000 copies/ml) virologic failure was more likely to be 
developed than in those with baseline VL <100,000 copies/ml (Kaplan-Meier failure 
estimates Log-rank p <0.001 (Figure 12)). Virological suppression rates were analysed at 
months 6, 12, 18, 24 among all patients according to intention-to-treat analysis which were 
76%, 72%, 67%, 64% and among patients on treatment 93%, 93%, 94%, 94%, 
respectively.  
 
 
 
Figure 12. Kaplan-Meier showed VL at baseline as a risk factor for virologic failure (Log-rank p-value 
<0.001). 
 
 
10.3 PAPER III 
 
Study background 
The aim of this paper was to adapt a phenotypic drug susceptibility assay, earlier 
developed for measurement of resistance to the first generation NNRTIs, nevirapine, and 
efavirenz, for the detection of resistance to the second generation NNRTI etravirine (ETR).  
 
The method was first optimised through titrations of the concentrations of ETR and other 
reagents in the assay. To evaluate the assay, five NNRTI resistant RT mutants were 
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produced (L100I, K103N, L100I/K103N, V179D, Y181C. As controls, T215Y and 
M41L/T69-SG/L210W/T215Y NRTI mutants were also included in the evaluation of the 
assay. All mutants were also tested for phenotypic susceptibility towards NVP to be able 
to confirm our previously published results on ExaVir Drug and NVP [127, 128, 143]. 
 
In order to correlate phenotype with genotype, 28 plasma samples from HIV-1 infected 
patients at Karolinska University Hospital were also analysed for further clinical 
evaluation of the assay. Plasma from 15 newly diagnosed presumably treatment-naïve 
patients and from 13 patients who had failed NNRTI containing therapy with ≥1400 
HIV-1 RNA copies/ml were selected. The ETR phenotype obtained using the ExaVir 
Drug assays was compared to the predicted ETR phenotype obtained by routine genotypic 
analyses. 
 
Inter- and intra-assay variability of the assay was also tested. The variation of the IC50 
value for ETR was measured by testing two plasma samples (3 and 7) from the Karolinska 
HIV cohort at three different occasions (run 1 to run 3), each time in quadruplicates. Intra-
assay means and SD (standard deviation) were calculated. Inter-assay SDs were calculated 
using the modified SD formula, [(SD of the assay means)
2
-(mean intra-assay SD)
2
/r]
½
 
where r is the number of replicates. The SD achieved was used to calculate the CV 
(coefficient of variation) by using the formula CV = (SD/mean) × 100. The effect of 
variation in the amount of RT on the IC50 value was a also tested by measuring the ETR 
susceptibility on two samples serially diluted in 2.5 fold steps ranging the RT amount of 
40-828 fg RT/ml plasma. 
 
Results and discussion 
Effects of NVP and ETR on recombinant HIV-1 RTs 
We found that the recombinant RTs had in general the expected drug susceptibility 
(Table 3). The RT with Y181C, L100I and L100I + K103N mutations, respectively, 
exhibited pronounced decreased susceptibility to the drugs. The K103N mutation yielded 
increased IC50 towards NVP, but not ETR. The RT with Y179D had a very slightly 
increased IC50, as compared to the controls. The wild-type strain HXB2 and T69S-SG 
mutations showed a similar susceptibility pattern for NVP and ETR. The RT mutant with 
T215Y showed a slight increase in the IC50 for NVP but not for ETR.  
 
In this paper we showed that both NVP and ETR displayed expected IC50 values for all 
recombinant HIV-1 RTs equivalent to previous reports [59, 127] and the test could 
plausibly detect ETR resistance associated with Y181C and L100I substitutions as well 
as discriminate between the impact of K103N on the IC50 value of NVP but the lack of 
impact on the IC50 value of ETR  [59, 144]. 
 
 34 
______________________________________________________________________ 
             IC50 (µM)      
                                                
RT analysed NVP  ETR  
_______________________________________________________________________ 
 
NNRTI substitution panel 
BH10*  1.1 ± 0.1 0.9 ± 0.2 
BH10 E478Q 3.6 ± 1.6 0.9 ± 0.2 
BH10 V179D, E478Q  8.2 ± 1.1 3.8 ± 1.0 
BH10 Y181C, E478Q >100 35.9 ± 9.8 
BH10 L100I, E478Q** 37.9 ± 11.9 13.4 ± 2.7 
BH10 K103N, E478Q 166.7 ± 11.7 1.4 ± 0.2 
BH10 L100I, K103N, E478Q 237.3 ± 8.3 50.1 ± 20.6 
 
NRTI substitution panel 
HXB2*** 3.3 ± 1.5 2.5 ± 0.4 
HXB2 T215Y 8.4 ± 0.3 1.4 ± 0.1 
HXB2 M41L, T69S-SG, L210W, T215Y 2.9 ± 1.8 1.5 ± 0.7 
________________________________________________________________________ 
Table 3. Effects of nevirapine and etravirine on recombinant HIV-1 RTs. Data are presented as mean IC50 
values and SD; IC50, 50% inhibitory concentration; NNRTI, non-nucleoside RT inhibitors; NRTI, 
nucleoside RT inhibitors; NVP, nevirapine; ETR, etravirine. Data are based on three experiments for ETR 
susceptibility, except 10 experiments for BH10*, L100I** and HXB2***. NVP susceptibility was repeated 
at least three times (BH10, HXB2 and L100I, were repeated seven, four and five times, respectively), 
except for Y181C that was estimated at one occasion. 
 
 
Reproducibility of ETR susceptibility and variation effect  
The reproducibility data for the two samples tested at three different occasions in four 
replicates showed inter assay variation (CVs) of 9.4 and 11.1% (Table 4). Data also 
showed that the IC50 values for ETR (mean ± SD: 1.6 ± 0.03 µM and 3.1 ± 0.04) were 
not influenced by the RT amount within the 40-828 fg/ml RT range (Figure 13).  
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Figure 13. Presents the effects of variations in the amount of RT on the IC50 value for ETR. ETR 
susceptibility was determined on two HIV- RTs isolated from patient sample 9 ■ and 4 ♦ and diluted to the 
indicated concentrations, ranging from 40 to 828 fg RT/ml. 
 
 
Patient 
tested 
Intra-assay variation in IC50 (µM) Inter-assay variation 
Run 1 Run 2 Run 3 Mean SD
 a
 CV (%) 
3 4.6 (±0.5) 5.5 (±0.4) 5.0 (±0.4) 5.2 0.48 9.4 
7 2.1 (±0.2) 2.5(±0.1) 2.1 (±0.2) 2.2 0.25 11.1 
 
Table 4.
  
Reproducibility data of ETR susceptibility. Two samples were tested on three independent 
occasions (run 1 to 3).  
a 
Inter-assay SDs were calculated using the modified SD formula, [(SD of the assay means)
2
-(mean intra-
assay SD)
2
/r]
½
 where r is the number of replicates. The SD achieved was used to calculate the CV by using 
the formula CV = (SD/mean) × 100. 
 
 
Effects of ETR on patients HIV-1 RT  
The potential clinical value of the method was determined by analysis of plasma 
samples. In all of the 15 samples from presumably treatment-naïve patients (Table 4), 
low IC50 values (mean ± SD: 2.5 ± 1.0 µM) were found for RT activity in the presence of 
ETR. In patient 3, however, sequencing revealed the presence of K103N most likely due 
to previous drug exposure or infection with a resistant variant. Also, in 13 NNRTI-
experienced patients who were failing ART we found a concordant result. Seven samples 
(16, 17, 23, 25, 26, 27 and 28) had low IC50 values (Table 4). The sequence analysis was 
consistent with the phenotypic results in three cases which lacked NNRTI mutations (25, 
27 and 28). In four cases (16, 17, 23 and 26), sequence analysis showed mutations which 
are not clearly associated with ETR resistance (16: K103N; 17: A98G+V179I; 23: 
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V179I; 26: K103N+V108I). The A98G has been reported to be associated with decreased 
ETR response in vivo but has little, if any, effect on ETR susceptibility. 
 
The remaining six samples had high (similar or higher than the IC50 value of the mutant 
control) IC50 (Table 4). The result concordantly showed high IC50 values in plasma RT 
with Y181C (samples 20, 21 and 22) and intermediate IC50 values were associated other 
known ETR associated mutations, confirming the reliability of our assay. However, for 
plasma RT which had intermediate IC50 values a few discordant results were found in 
comparison with genotypic outcome. E.g. in a patient whose subtype C virus exhibited a 
K103N mutation, a slightly increased IC50 was obtained at several repeated analyses. 
Since the standard sequencing only validates the major viral population, the possibility 
cannot be excluded that the genotypic assay failed to detect minor quasispecies 
contributing to the slightly increased IC50 values to ETR detected here. However, an in-
house allele-specific PCR could not identify any Y181C minor quasispecies. 
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   Mutations at amino acid  
Patient NNRTI fg RT/ml ETR 98 100 101 103 108 179 181 188 190 Antiviral score according to RNA HIV 
   IC50 (M) A L K K V V Y Y G Stanford Tibotec Monogram copies/ml subtype 
BH10 NA NA 0.9±0.16          ND ND ND NA B 
L100I NA NA 13.0±2.9  I        ND ND ND NA B 
1 None 16 1.8          0 0 0 1800 C 
2 None 159 3.4          0 0 0 66000 C 
3 None 682 5.2±0.54    N      0 0 0 n/a C 
4 None 828 1.6±0.04          0 0 0 n/a C 
5 None 28 1.4          0 0 0 n/a C 
6 None 357 1.8          0 0 0 n/a C 
7 None 32 2.3±0.32          0 0 0 n/a C 
8 None 70 1.4          0 0 0 n/a C 
9 None 628 3.1±0.07          0 0 0 n/a C 
10 None 21 2.8          0 0 0 7900 CRF01 AE 
11 None 91 2.4          0 0 0 14000 A 
12 None 106 2.3          0 0 0 16700 B 
13 None 105 2.5          0 0 0 27700 A 
14 None 437 3.4          0 0 0 56800 B 
15 None 181 2.4          0 0 0 18100 CRF01 AG 
16 EFV 45 1.2    N      0 0 0 12000 B 
17 NVP 276 3.9 G     I    5 1 0 62000 A 
18 EFV 98 14.5 G  E N I     15 2 2 17000 B 
19 EFV 33 8.5 G   N    F  5 1 0 4200 B 
20 NVP 203 >100      E C   35 2.5 7 44000 CRF06 CPX 
21 NVP 201 >100 G      C   35 3.5 4 24000 A 
22 NVP 6 20.0 G     I C   35 3.5 4 6300 A 
23 NVP 329 2.5      I    0 0 0 183000 A 
24 EFV 25 17.6   KE N      15 0 0 11000 B 
25 EFV 731 4.1          0 0 0 261000 B 
26 EFV 3 4.9    N I     5 0 0 1500 C 
27 EFV 574 4.1          0 0 0 29000 C 
28 EFV 434 2.8          0 0 0 54000 C 
Table 4. Effects of etravirine on HIV-1 RT recovered from plasma of HIV-1 infected patients. Genotypic and phenotypic characterisation was performed on HIV-1 (expressed as fg RT/ml) from 
patients without treatment (1-15) or with NNRTI containing treatment (16-28). If no standard deviation is indicated, experiments were run at single occasions. The two reference recombinants RT, 
(BH10)-wild-type (WT) and its mutant form L100I, were tested in 14 experiments. Three genotypic scoring systems (Stanford, Monogram, Tibotec) defining predicted ETR susceptibility are presented. 
HIV-1 subtypes were defined by the pol gene. Abbreviations: NA, not applicable; n/a, not available; IC50, inhibitory effect; NNRTI, non-nucleoside RT inhibitors; ETR etravirine; NVP, nevirapine; 
EFV efavirenz. 
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The correlation between the scoring systems (Tibotec (r=0.60 p <0.001), Monogram 
(r=0.63 p <0.0004), and Stanford (r=0.80; p <0.0001)) and outcome of the method was 
significant for all algorithms despite that known ETR RAMs were detected in only 54% 
of patient isolate (7/13) by direct sequencing. As these scores are mostly directed to 
balance the major ETR mutations the differences between phenotypic and genotypic 
assays are not unexpected [145]. 
 
To summarise this paper, as general finding, the changes in IC50 values for ETR (and 
NVP) correlated well with the predicted results from direct sequencing of the pol region. 
The ExaVir Drug approach has previously been applied for NVP with success [127, 128] 
and its usefulness was confirmed in this paper and extended to ETR. In order to describe 
a more precise laboratory cut-off for decreased susceptibility and a clinically relevant 
cut-off, a more extensive evaluation has to be performed. However, we believe that this 
phenotypic RT drug susceptibility assay could be a low cost alternative for to genotyping 
or conventional phenotyping in limited resource settings in studying resistance to first 
and second generation NNRTIs.  
 
10.4 PAPER IV 
 
Study background 
The aim of this paper was to perform a further clinical evaluation of our newly adapted 
RT-based assay for assessment of resistance to ETR in patients with past or ongoing failure 
on the first generation NNRTIs. We compare RT phenotype with the genotype obtained 
with standard direct sequencing. In those cases where there was a discrepancy between the 
major genotype and the RT phenotype, ultra-deep pyrosequencing (UDPS) was also 
performed to identify any minor sequence variants in the HIV-1 RT gene. Two reference 
recombinants RT´s, BH10-wild-type and its mutant form L100I were included in the 
analyses of the RT-based phenotypic assay. 
 
Altogether, 25 plasma EDTA samples of 20 HIV-1 infected patients (Table 5) were 
retrospectively included from the HIV cohort at Department of Infectious Diseases, 
Karolinska University Hospital, Stockholm, Sweden and analysed for ETR resistance by a 
reverse-transcriptase based phenotypic assay.  
 
Of these, 15 treatment-experienced patients were randomly selected among subjects with 
ART failure. For eight samples the failing regimen contained an NNRTI. For 12 samples, 
the NNRTI had been stopped earlier and the failing regimen contained now antiretroviral 
drugs from other categories. Four treatment naïve patients were also included since they 
had been infected with NNRTI-resistant strains.  
 
Genotypic resistance test, GRT, had been performed within the clinical care by direct 
sequencing of the pol gene in all of these individuals and one or more NNRTI mutations 
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had been found in all of them, except in one patient (patient 7). One NNRTI-naïve patient 
(patient 4), who had a K103R mutation, was also chosen as a negative control since this 
mutation is reported not to affect ETR susceptibility.  
 
Pat.* 
 
Sex* Age* Sub- 
type 
Ongoing 
NNRTI 
treatment** 
Earlier 
NNRTI 
treatment*** 
Other ongoing 
drugs**** 
HIV load 
(copies/ml) 
CD4 
count 
(cells/µl) 
1 m 37 D no EFV (-134), 
NVP (-6) 
no 17800 200 
2 m 43 B no no no 292000 100 
3a m 41 B no EFV (-472) no 161000 10 
3b    ETR (111) EFV (-585) DRV/r 117000 10 
4 m 52 B no no no 63000 373 
5a m 61 B EFV (236) - LPV/r, T20 21800 300 
5b    EFV (248) - LPV/r, T20 47000 335 
6 f 48 C no EFV (-250), 
NVP (-60) 
TDF, FTC, T20 6700 155 
7 m 56 C no EFV (-286) ATV,TDF,ABC,3TC 1500000 22 
8a m 46 B NVP (337) EFV (-418) ABC, 3TC, TDF 13100 126 
8b    NVP (339) EFV (-420),  ABC, 3TC, TDF 3920 126 
9a m 61 B no EFV (-422), 
NVP (-192) 
LPV/r, 3TC, RAL 8400 209 
9b    no EFV (-448), 
NVP (-218) 
LPV/r, 3TC, RAL 20000 246 
10 m 49 B NVP (262) EFV (-286) ABC,3TC,TDF,T20 10400 662 
11a f 49 A EFV (180) - ABC, 3TC 2600 260 
11b    no EFV (-308) no 12200 219 
12 m 42 C no NVP (-18) ATV/r, ABC, 3TC 1100 380 
13 f 40 C no no no 151000 9 
14 m 53 B no EFV(-172) no 100001 420 
15 m 51 B no EFV (-308) DRV/r, TDF, FTC 910000 40 
16 f 36 A no no no 4420 303 
17 f 42 D no NVP (-19) ABC, 3TC, ZDV 1900 159 
18 m 49 D NVP (11) EFV (-220) ABC, 3TC, ZDV 12000 345 
19 m 49 B no no no 29000 234 
20 f 49 B no EFV (-8) no 4700 400 
 
Table 5.  Characteristics of 20 HIV-1 infected patients with antiretroviral treatment failure at the time of plasma 
sampling. *Patients were selected due to a failing ART with the exception of patients no 2, 13, 16, 19 who were 
infected with an NNRTI-resistant strain; a and b indicate a first and a second sample;  m: male; f: female; age: 
years;**Figure within brackets indicate the number of weeks from the start of the last ongoing NNRTI-treatment to the 
sampling date. ***Figure within brackets indicates the number of weeks from cessation of the prior NNRTI-containing 
treatment to the sampling date.****ABC: abacavir; 3TC: lamivudine; FTC: emitricitabine; TDF: tenofovir; ZDV: 
zidovudine: LPV/r: lopinavir/ritonavir; ATV/r: atazanavir/ritonavir: DRV/r: darunavir/ritonavir; RAL: raltegravir; 
T20: enfuvirtide. 
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To be able to predict ETR susceptibility, three genotypic scoring systems were used, 
Stanford University, Monogram Weighted Score, Tibotec Weighted Genotype Score. The 
correlation between Monogram/Tibotec/Stanford scorings and IC50 determined by our 
phenotypic RT assay was assessed by Spearman´s rank test using software in GraphPad 
Prism version 5 (San Diego, California, USA). 
 
Results and discussion 
Phenotypic assay results in relation to mutational patterns 
RT was isolated from 20 plasma samples from 15 patients with treatment failure (Table 6).  
In ten samples (3a, 4, 7, 9a, 11b, 12, 15, 16, 17, 18) with the lowest IC50 values (mean ± 
SD: 3.1 ± 1.3; range: 0.7 - 4.5 µM), there was a good concordance with the GRT. Thus, 
sequence analysis showed no mutations or non-ETR RAMs.   
 
Six samples had IC50 values which according to our earlier evaluation [146] can be 
considered as slightly increased (range: 6.4 – 13.6 µM; 1: 11.8 µM, 9b: 9.2 µM, 10: 13.6 
µM, 11a: 7.3 µM, 19: 6.4 µM, 20: 7.2 µM). In all of them only non-ETR RAMs were 
found. Four samples of three patients showed increased IC50 values (5a: 45.8 µM; 5b: 71.4 
µM; 13: 68.8 µM 14: 29.1 µM), while direct sequencing showed mutations which are not 
known to be predictive for decreased sensitivity for ETR (5a and 5b: K101I/R+V106G; 13: 
K103N+G190A; 14: A98S+K103N+E138A). Five samples (2, 3b, 6, 8a, 8b) had strongly 
increased IC50 (>100 uM). The mutational patterns were, to varying degree, predictive of a 
decreased sensitivity to ETR, including Y181C (3b, 8a, 8b), V901+L100I+K103N (6), and 
A98S+E138E/Q+K238T (2). The correlation between the Stanford scoring system and the 
phenotypic assay results (r = 0.70 p <0.0001) was significant. The Monogram and Tibotec 
scoring systems also correlated with the IC50 values (r=0.65 p<0.0005; r=0.64 p<0.0005, 
respectively).  
 
One possible explanation for the discrepancy between the phenotypic and the genotypic 
test results obtained by direct sequencing is resistance in minor viral variants. Therefore, 
UDPS was used in nine samples in which a discrepancy was found. 
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  Mutations at amino acid Antiviral score according to 
Patient/ 
Sample 
ETR 
IC50 (µM) 
90 
V 
98 
A 
100 
L 
101 
K 
103 
K 
106 
V 
108 
V 
138 
E 
179 
V 
181 
Y 
188 
Y 
190 
G 
238 
K 
Stanford Tibotec Monogram 
BH10* 1.0±0.18              NA NA NA 
L100I* 12.0±2.3              15 2.5 4 
1 11.8  S    A        0 0 2 
2 >100     N   Q     T 10 1 2 
3a 4.5  S       D     10 1 1 
3b >100 I S       D C    45 4.5 6 
4 3.9     R         0 0 1 
5a 45.8    I/R  G        0 0 0 
5b 71.4    I/R  G        0 0 0 
6 >100 I  I  N         20 3.5 5 
7 0.7              0 0 0 
8a >100     N     C    30 2.5 4 
8b >100     N     C    30 2.5 4 
9a 4.6  S   N  I      T 0 0 1 
9b 9.2  S   N  I      T 0 0 1 
10 13.6     N  I       0 0 0 
11a 7.3     N    I     0 0 1 
11b 4.1         I     0 0 1 
12 2.0     N         0 0 0 
13 68.8     N       A  10 1 1 
14 29.1  S   N   A      5 1.5 3 
15 2.9     N         0 0 0 
16 1.7     N         0 0 0 
17 2.9     N         0 0 0 
18 4.1 I    N         0 1 1 
19 6.4     N         0 0 0 
20 7.2      N         0 0 0 
Table 6. Effects of etravirine on HIV-1 reverse transcriptase, recovered from plasma of HIV-1 infected patients. * Two recombinant reverse transcriptase, (BH10)-wild-type 
(WT) and its mutant form L100I, were used as references. Abbreviations: NA, not applicable; IC50, inhibitory effect; ETR etravirine.**Genotype  result was obtained six months 
earlier. The results of three genotypic scoring systems (Stanford, Monogram Weighted Score, Tibotec Weighted Genotype Score) predicting ETR susceptibility are presented. A 
Stanford score of 0-<15, ≥15-<60 and ≥60 are defined as susceptible, intermediate and resistant. Tibotec weighted genotypic score of  0-2, 2.5-3.5 and ≥4 are predictive of 
susceptible, intermediate and reduced response. Monogram defines a weighted score of 0-3 as susceptible and ≥4 as resistant. 
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Ultra-deep pyrosequencing (UDPS) results 
UDPS was performed on nine samples (1, 2, 5b, 10, 11a, 13, 14, 19, 20) for which there 
seemed to be a discrepancy between the major genotype and the RT phenotype (Table 7). 
When direct sequencing was compared with UDPS, all mutations corresponding to >20% 
were detected and no mutations corresponding to <20% of the viral population. Altogether 
eleven mutations were detected by UDPS, but not by direct sequencing, ranging from 
0.54% to 19.56%. There was a concordance between the direct sequencing and the UDPS 
for mutations consisting of >20% of the viral population. Also, eleven additional RAMs 
were found by UDPS, in all cases <20% of the viral population, which is well in line with 
earlier results on the detection levels of direct sequencing [107, 108, 110, 147]. 
 
In four of the samples (1, 11a, 13, 14), the UDPS detected minor variants including such 
which are associated with decreased ETR susceptibility and may have contributed to the 
phenotypic resistance explaining the discrepancy with the genotype obtained by direct 
sequencing. 
 
In three samples (2, 5b, 20), identical mutations were found with the two sequencing 
techniques. Thus, the UDPS did not revealed any further minor variants that could explain 
the increased IC50 values of 100 µM, 71.4 µM and 7.2 µM, respectively. 
In the remaining two samples (10, 19), the UDPS showed additional minor mutations not 
known to be associated with decreased ETR susceptibility. 
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   Mutations at amino acid* Antiviral score according 
to 
Patient/ 
Sample 
ETR 
IC50 (µM) 
 90 
V 
98 
A 
100 
L 
101 
K 
103 
K 
106 
V 
108 
V 
138 
E 
179 
V 
181 
Y 
190 
G 
238 
K 
Stan Tibo Mon 
1 11.8 Direct  S    A       0 0 2 
  UDPS  S    T A I  I C   30 2.5 7 
  **2409(1127-3244)  *68.63%   18.8% 66.58% 0.54%  0.57% 6.88%      
2 >100 Direct     N   Q    T 10 1 2 
  UDPS     N   Q    T 10 1 2 
  1958 (1108-2870)     99.2%   32.47%    98.64%    
5b 71.4 Direct    I/R  G       0 0 0 
  UDPS    I/R  G       0 0 0 
  2305(1201-3397)    65.64%/ 
31.09% 
 99.83%          
10 13.6 Direct     N  I      0 0 0 
  UDPS     N  I  I    0 0 1 
  1704(876-2325)     98.85%  100%  3.24%       
11a 7.3 Direct     N    I    0 0 1 
  UDPS     N    I  A  10 1 2 
  1613(873-1887)     97.44%    100%  3.59%     
13 68.8 Direct     N      A  10 1 1 
  UDPS I  I  N      A  25 6 4.5 
  2506(1546-2696) 2.26%  0.61%  99.41%      95.57%     
14 29.1 Direct  S   N   A     5 1.5 3 
  UDPS  S  E N   A    T 15 2.5 6 
  1855(1118-2536)  96.77%  0.81% 22.1%   100%    19.56%    
19 6.4 Direct     N        0 0 0 
  UDPS     N/S I       0 1.5 2 
  1499(832-2325)     95.07%/ 
3.05% 
1.09%          
20 7.2 Direct     N        0 0 0 
  UDPS     N        0 0 0 
  2412(1228-2953)     97.37%           
 
Table 7. NNRTI-resistance results obtained through phenotypic testing, direct sequencing and ultra-deep sequencing (UDPS). ETR = etravirine; Direct = Direct Sanger sequencing; UDPS = Ultra-Deep 
Pyrosequencing; Stan = Stanford; Tibo = Tibotec; Mono = Monogram. *figure beneath amino acid indicate percentage consisting of a mutated population as determined by UDPS. ** Median (IQR) 
nucleotide coverage per patient.
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Clinical interpretation of the resistance results: 
Resistance results in patients who had stopped NNRTI. Twelve samples (1, 3a, 6, 7, 9a, 9b, 
11b, 12, 14, 15, 17, 20) of eleven patients were drawn after that an NNRTI containing 
regimen had been terminated (Tables 5). In patients 1 and 20, NVP and EFV had been 
stopped six and eight weeks earlier, respectively. The IC50 values (Table 6) were slightly 
increased (11.8 µM and 7.2 µM, respectively) but the Stanford scoring predicted full 
sensitivity (A98S+V106A; K103N, respectively). However, in patient 1 UDPS revealed 
additional minor mutations (K103T+V108I+V179I +Y181C) which possibly could explain 
this difference (Table 7). In patients 6 and 14, a clear decreased phenotypic sensitivity 
against ETR (6: >100 µM; 14: 28.8 µM) was found despite that >1 year and > 3 years, 
respectively, had passed since the cessation of an NNRTI. The genotyping further 
supported this finding for patient 6 (direct sequencing: V90I+L100I+K103N) and patient 
14 (UDPS: A98S+K101E+K103N+E138A+K238T).  
 
In four patients, several years had passed since their NNRTI treatment was terminated (7, 
11b, 15: >5.5 years; 9a: 3.5 years). In patient 12, 18 weeks had passed. No phenotypic 
resistance was found in these patients although non-ETR RAMs persisted (11b: V179I; 12 
and 15: K103N; 9a: A98S+K103N+V108I+K238T). However, a second sample of patient 
9 drawn four months later showed a slightly decreased phenotypic sensitivity (9.2 µM) 
with the same mutational pattern with a concomitant increase in plasma viral load. UDPS 
could not be performed due to lack of plasma.  
 
Resistance results in patients with ongoing NNRTI failure. Eight samples (3b, 5a, 5b, 8a, 
8b, 10, 11a, 18) of six patients were drawn during failure of an NNRTI containing regimen. 
In four samples (3b, 8a, 8b, 18), a concordance was seen between the pheno- and genotype. 
Thus, patient 3b exhibited a high ETR resistance with both methods (IC50: >100 µM; 
genotype: V90I+A98S+V179D+Y181C). In both samples of patient 8, phenotypic 
resistance (>100 µM) and the mutations K103N+Y181C were found. Patient 18 had a 
sensitive phenotype (4.1 µM) and was devoid of mutations other than K103N+V90I after 
10 weeks failure.  
 
In four samples, disconcordance was seen between the RT-based phenotype and the 
genotype. In patient 5, two samples were drawn with three months interval during failure 
with EFV-containing regimen. An increasing IC50 of 45.8 µM and 71.4 µM, respectively, 
was seen despite that direct sequencing as well as UDPS showed only mutations 
(K101I/R+V106G) which are not known to be ETR-associated. Patient 10 exhibited an 
increased IC50 (13.6 µM), but the identified mutations (direct sequencing: K103N+V108I; 
UDPS: K103N+V108I+V179I) predicted an ETR sensitive virus. In patient 11 a sample 
drawn early after failure showed a slightly increased IC50 (7.3 µM), while the direct 
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sequencing showed K103N+V179I. However UDPS identified additionally G190A giving 
support for that resistance was developing.  
 
Effects of ETR on patients with transmitted NNRTI resistance. Four patients (no 2, 13, 16, 
19), who had been infected with an NNRTI resistant strain, were also analysed. Patients 2 
and 13 had a strongly increased IC50 value (>100 µM; 68.8 µM) despite that the sequence 
analysis predicted only a slightly decreased sensitivity (2: K103N+E138Q, K238T; 13: 
K103N+G190A) (Table 2). The remaining two samples had the K103N only, and a low 
1.7 µM (16) and a slightly increased 6.4 µM (19) IC50 value, respectively, was found. 
 
To summarise this paper, our RT-based phenotypic assay showed decreased ETR 
susceptibility in patients where direct sequencing predicted ETR-sensitive virus. The 
clinical treatment history was concordant with that our phenotypic results corresponded to 
a true decreased susceptibility for ETR. Thus, during early ART failure and before the 
NNRTI was stopped, an increase of the IC50 was seen in four of eight samples despite that 
a sensitive virus was predicted by the genotype. Also, in two patients who stopped NNRTI 
some weeks before the sampling, an increased IC50 but not ETR-resistance mutations was 
found. For subjects who had stopped the first generation NNRTI-containing regimen for 
one or more years, a good concordance between the methods was seen. In addition, in two 
subjects (7 and 16) with very poor adherence, no phenotypic resistance was identified and 
only K103N in one of them. These patient histories and the UDPS comparison indicate that 
our phenotypic method may detect resistance to ETR despite that the direct sequencing 
predicts a sensitive phenotype. 
 
The clinical utility of the phenotypic method remains to be established. It is clear that there 
is a strong correlation between the results of our phenotypic method and the predicted 
antiviral scores according to three genotypic scoring systems. A high IC50 was found in all 
samples with key-mutations, Y181C and L100I, which are associated to ETR resistance. 
However, in a substantial number of samples there was a phenotypic decreased 
susceptibility but no known ETR-RAMs. The clinical relevance of these findings and 
clinical cut off of our method can only be studied on larger patient-populations. Even so, 
this study showed that the adaptation of the RT based phenotypic test for detection of ETR 
resistance in plasma is possible. The assay is simple to perform, uses basic laboratory 
equipment, and does not require complex interpretations. This phenotypic RT drug 
susceptibility assay could therefore be a low cost alternative for studying resistance to first 
and second generation NNRTI and useful for studies on the kinetics of NNRTI resistance 
during ART failure.  
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11 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Although ART has reduced HIV-1 associated morbidity and mortality, development of 
drug resistance has become a major problem. Ideally, when ART is rolled out in 
resource-limited settings, it should be coupled to virological monitoring. However, due 
to a high cost and lack of technical equipment and expertise, this is frequently not 
available. This increases the risk of undetected treatment failure and the development 
of widespread drug resistance. 
The prevalence of transmitted drug resistance (TDR) is of importance for determining 
the choice of 1
st
 line ART, which in Vietnam and other LMICs consists of NNRTI-
based ART. In Paper I the prevalence of TDR was 6.3%, which is slightly higher 
compared to other recent studies from South-East Asia. Nonetheless, apart from one 
patient whose virus had Y181C mutation, the TDR detected are of limited clinical 
importance and do not rule out the use of the standard first-line treatment regimen. 
However, in view of the increasing use of different antiretroviral drugs in Vietnam it is 
important to regularly monitored prospectively in Vietnam. 
In Paper II we showed that the RT VL assay was a useful tool for monitoring VL and 
feasible for monitoring virological outcome and assess ART efficacy in Vietnam. The 
RT VL assay also displayed a strong correlation with Cobas TaqMan PCR and showed 
similar sensitivity to the PCR-based method. This, together with the fact that the RT 
assay requires only basic laboratory equipment, makes the test an alternative technique 
for developing countries. Having access to VL can facilitate early detection of drug 
failure and aid in enhancing early adherence support and the choice of new therapy 
regimes, thereby preventing the emergence of more advanced drug resistance patterns. 
Keeping in mind that most ART programs in LMICs are presently based on a limited 
number of drugs, implementing these programs without simultaneous implementation 
of VL testing is risky, as initial treatment gains will be ultimately lost to future drug 
failures and spread of resistant viral strains. 
Assays using RT purified from the virus particles of a patient sample allow both for VL 
quantification and assessment of phenotypic drug susceptibility, the latter being 
important not only at initiation of ART but also at therapy switch after treatment 
failure. The RT-based methodology has earlier been described for measuring 
phenotypic drug susceptibility to the first generation NNRTIs (EFV and NVP) [127, 
128, 143]. In Paper III we showed that the RT-based phenotypic resistance assay can 
be used for detection of resistance also to the second generation NNRTI ETR, 
including cross-resistance to other NNRTIs, in clinical samples. Low IC50 values were 
shown in treatment-naïve patients. Furthermore, a good reproducibility was 
demonstrated, with the outcome of the test being independent on the amount of plasma 
HIV RNA. Also, in treatment naïve-patients, the result concordantly showed high IC50 
values in plasma RT where Y181C was detected by direct sequencing. Intermediate 
IC50 values were associated with other known ETR associated mutations, confirming 
the reliability of our assay.  
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In Paper IV a further thorough clinical evaluation of the RT-based resistance assay 
was performed in patients with past or ongoing failure with first generation NNRTIs. 
Most of the strains had a various degree of decreased ETR susceptibility as measured 
by the phenotypic test. However, the mutational patterns based on direct sequencing did 
not always predict ETR resistance, potentially indicating that the assay may 
overestimate the presence of decreased drug susceptibility. Nevertheless, in Paper III 
ETR gained expected changes in IC50 values for all recombinant HIV-1 RTs equivalent 
to previous report [59, 127]. Thus, it is clear that the method can discriminate between 
mutants with or without ETR RAMs. One possible explanation for the discrepancy 
between the phenotype and the genotypic test results obtained by direct sequencing can 
be resistance in minor viral variants. In Paper IV we analysed patient samples with 
unexpectedly high IC50 values with UDPS, and found minor viral populations with 
ETR RAMs in four of the nine samples. In at least three of them, the proportion of 
mutated virus was sufficiently high to provide a potential explanation for the 
discrepancy between phenotype and the genotype obtained by direct sequencing. This 
indicates that our phenotypic method may in fact be more sensitive than direct 
sequencing in identifying minor quasispecies with RAMs in the RT gene. Also, the 
clinical treatment history for the patient included in Paper IV was concordant with that 
our phenotypic results corresponded to a true decreased susceptibility for ETR. The 
patient histories and the UDPS comparison indicate that our phenotypic method may 
detect resistance to ETR despite that the direct sequencing predicts sensitive phenotype. 
The cause of the discrepancies between the phenotype and the genotype results is not 
known presently. The mutations predictive for cross-resistance to ETR-resistance have 
been mainly identified in clinical studies using direct sequencing and it cannot be 
excluded that not-yet described mutations exist which may influence the ETR 
sensitivity. The effects of defined mutations may also vary in different genetic 
environments. Our phenotypic method uses lysates originating from intact virions. The 
genotypic and phenotypic method based on recombinant viruses use HIV RNA which 
partly may represent defective virus [148], therefore it can be speculated that our 
phenotypic assay is more representative for the ongoing viral replication. 
 
A less costly and technically simple test such as the RT assay presented in this thesis 
could be considered for VL monitoring and resistance testing as alternatives to 
conventional HIV RNA quantification by Roche Cobas TaqMan PCR and direct 
sequencing, in regions where expensive molecular-based methods are not a viable 
alternative. ExaVir Load was successfully used in a Uong Bi General hospital in 
northern Vietnam, and its implementation in other settings should still be possible 
provided basic laboratory equipment such as a spectrophotometer and an incubator are 
available. Regarding, the phenotypic assay for detection to ETR resistance, to describe 
a more precise laboratory (technical) IC50 cut-off for decreased drug susceptibility an 
extensive evaluation has to be carried out. Although, access to ETR in LMICs still is 
limited, ETR may be of relevance for LMICs since resistance to the first generation 
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NNRTIs as well as to NRTIs is an increasing problem in treatment of HIV-1 infected 
patients in resource-limited settings. 
Although, a further evaluation is needed to define clinical cut-offs we believe that the 
RT-based assay may be an alternative to more costly HIV drug resistance tests, 
especially in LMICs. The possible use for measuring resistance towards NRTIs as well 
as the other second generation NNRTI, RPV, may also be of interest since RT 
inhibitors are widely used both in high- and low-income countries. 
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